WHO ICTRP trial
An exploratory study of Camrelizumab combined with chemoradiotherapy in the…
ChiCTR2000038637 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2000038637 |
|---|---|
| Public title | An exploratory study of Camrelizumab combined with chemoradiotherapy in the treatment of recurrent/metastatic gynecological cancers |
| Scientific title | An exploratory study of Camrelizumab combined with chemoradiotherapy in the treatment of recurrent/metastatic gynecological cancers |
| Primary sponsor | The Fourth Hospital of Hebei Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | gynecological cancers |
| Interventions | Experimental group:Camrelizumab combined with chemoradiotherapy |
| Registration date | Sep 26, 2020 |
| Target size | Experimental group:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: